Vimarsana
Biggest News Aggregation in the World

Page 16 - Memory Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Memory Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Memory Disorders Today - Breaking & Trending Today

Your Wordle Obsession Might Actually Good For You | Hot 101.9 - Vimarsana News

Your Wordle Obsession Might Actually Good For You | Hot 101.9

Want to know more about Jay Steele? Get their official bio, social pages & articles on Hot Mix 101.9!

Source: iheart.com
This week at the Mancini Center - Vimarsana News

This week at the Mancini Center

NORTH PROVIDENCE – The North Providence Mancini Center, 2 Atlantic Blvd., announces the following programs.

Outrage, Praise for CMS' Proposed Aducanumab Payment Policy - Vimarsana News

Outrage, Praise for CMS' Proposed Aducanumab Payment Policy

Reaction to the Centers for Medicare & Medicaid Services' proposed decision to restrict coverage of the controversial and expensive Alzheimer's disease drug aducanumab has been swift and polarized.

New Sanders-Brown Center on Aging Memory Clinic Expanding Research and Enhancing Patient Care - Vimarsana News

New Sanders-Brown Center on Aging Memory Clinic Expanding Research and Enhancing Patient Care

The world looks to The University of Kentucky’s Sanders-Brown Center on Aging for answers to the mysteries of dementia, and the elderly rely on them for help in charting their path to a healthy and vigorous senior lifestyle. After outgrowing their space along North Broadway in Lexington, leaders at UK decided it was time that Sanders-Brown’s home for clinical research and patient care reflects their reputation — building them a new home on UK HealthCare’s Turfland Campus.

Source: uky.edu
Doctors Are Urging Medicare to Deny Coverage for Controversial Alzheimer's Drug - Vimarsana News

Doctors Are Urging Medicare to Deny Coverage for Controversial Alzheimer's Drug

The FDA has faced sharp criticism for approving Aduhelm even though clinical trials exposed serious safety risks.